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Abstract
Objective: Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by elevated platelet counts 
and increased risk of thrombosis. Ex vivo data suggest increased platelet reactivity in agreement with the increased 
thrombosis risk, while in vitro tests often detect decreased platelet activity. The present study aimed to investigate adhesion 
of ET-platelets in vitro, which is an aspect of platelet function that has been addressed in only a few studies on ET patients. 
Material and Methods: The study included 30 ET patients and 14 healthy controls. Platelet adhesion was measured with 
a static platelet adhesion assay. 
Results: The main finding was that ET-platelets were more readily activated by adhesion-inducing stimuli in vitro than control 
platelets. This was particularly evident in elderly patients and when using multiple stimuli, such as surfaces of collagen or 
fibrinogen combined with addition of adenosine 5’-diphosphate or ristocetin. Such multiple stimuli resulted in adhesion above 
the control mean +2 standard deviations for approximately 50% of the patients.
Conclusion: The results are in accordance with the concept of increased platelet activity in ET, but opposite to most other 
in vitro studies. We suggest that the conditions in the adhesion assay might mimic the in vivo situation regarding the 
presence of chronic platelet activation. 
(Turk J Hematol 2010; 27: 82-90)
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Özet
Amaç: Esansiyel trombositemi (ET) platelet sayısının artması ve yüksek tromboz riski ile karakterize kronik bir myeloproli-
feratif bozukluktur. Ex vivo veriler tromboz riskine uygun olarak artan platelet reaktivitesini öne sürerken in vitro testler 
sıklıkla platelet aktivitesinde azalma tespit etmektedir. Bu çalışmanın amacı ET-hastalarında az sayıda çalışmaya dahil 
edilmiş bir platelet fonksiyonu konusu olan ET-plateletleri adezyonunun in vitro incelenmesidir. 
Yöntem ve Gereçler: Çalışmaya 30 ET hastası ile 14 sağlıklı kontrol dahil edilmiştir. Statik platelet adezyonu tayini ile plate-
let adezyonu ölçülmüştür. 
Bulgular: Temel bulgu ET plateletlerinin, in vitro adezyon indüklenmiş uyaranlar ile kontrol plateletlerinden daha kolay aktive 
olduğu olmuştur. Bu durum özellikle yaşlı hastalarda ve adenosin 5-difosfat ya da ristosetin eklenerek kombine edilmiş kolajen 
ya da fibrinojen yüzeyler gibi çoklu uyaran kullanıldığında barizdir. Bu gibi çoklu uyaran hastaların yaklaşık %50’sinde kontrol 
değeri + 2 standart sapmanın üzerinde adezyon sonucunu vermiştir. Financial support: The study was financed by grants from 
the County Council of Östergötland (2004/049 and LIO-5311). 
During the course of the research underlying this study, 
Andreas C. Eriksson was enrolled in Forum Scientium, a mul-
tidisciplinary doctoral program at Linköping University, Sweden. 
Introduction
Essential thrombocythemia (ET) is classified as a myelopro-
liferative neoplasm (MPN) [1] and affects about 1.5 middle 
aged to elderly individuals per 100,000 annually [2]. The dis-
ease is characterized by increased platelet counts and the 
occurrence of both thrombosis and bleeding [3]. Bleeding 
events are more common at very high platelet counts [4], prob-
ably as a consequence of the development of an acquired von 
Willebrand disease [5-7]. The most common complication is, 
however, thrombosis [3], which most often occurs in patients 
older than 60 years of age and in those with previous throm-
bosis [8]. Furthermore, a single point mutation in the JAK2 
gene (Val617Phe) has been described [9-11], and is estimated 
to be present in about 60% of patients with ET [12]. The impact 
of this mutation on the risk of thrombotic complications is still 
controversial [13,14]. Treatment alternatives in ET include the 
use of cytotoxic drugs to lower platelet number and/or use of 
the platelet inhibitor acetylsalicylic acid (ASA) [15]. Guidelines 
for the use of these drugs were recently prepared after review-
ing 438 papers published from 1980 to August 2002 [16]. It 
was concluded that treatment with ASA should be highly rec-
ommended for secondary thrombotic prophylaxis and for 
patients suffering from microcirculatory disturbances. However, 
the authors also discussed the lack of larger studies for this 
uncommon disease leading to difficulties in retrieving good 
scientific evidence for the best treatment in ET. Consequently, 
no consensus could be reached regarding ASA treatment as 
primary thrombotic prophylaxis. 
One way of approaching this problem is to conduct further 
research on platelet function and on the thrombotic process in 
ET. Knowledge from such studies might be used to detect 
individual patients and/or define novel high-risk patient groups 
that would benefit from ASA. Several studies investigating 
platelet function in ET have already been performed. However, 
interpretations of the results are complicated since, depending 
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Table 1. Demographics of the included patients
Gender (Male / Female) - n  8 / 22
Median age at blood sampling – years (range)  67 (30-87)
Median age at diagnosisa – years (range)  61 (31-84)
Median time from diagnosis to blood samplinga – years (range)  7 (1-27)
Treatment at blood sampling – n (%)
- ASA  10 (33.3)
-  ASA + Hydroxyurea  6 (20.0)
- No  treatment  5 (16.7)
- Hydroxyurea  4 (13.3)
-  Warfarin + Hydroxyurea  2 (6.7)
-  Warfarin + ASA  1 (3.3)
- Warfarin  1 (3.3)
- Interferon  1 (3.3)
Disease historyb – n (%)
- Thrombosis  9 (30.0)
- No  complications  11 (36.7)
- Bleeding  6 (20.0)
-  Thrombosis + Bleeding  4 (13.3)
aDetails are missing for one patient
bDisease history includes events occuring before the time of blood sampling. Thrombosis events include deep vein thrombosis, thrombophlebitis, stroke, angina/myocardial 
infarction and transitory ischaemic attack. Bleeding events include haematoma, excessive menstruation, gum bleedings, haematuria, excessive bleedings from wounds, 
epistaxis and spontaneous bleedings
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ET-platelets have been reported [17]. In the present study, we 
used a novel assay of static platelet adhesion [18] to investi-
gate platelet function in ET patients. The study used a screen-
ing approach and investigated adhesion to albumin, collagen, 
fibrinogen, and fibronectin in the presence of soluble activators 
such as adenosine 5’-diphosphate (ADP), adrenaline, ristocetin 
and L-α-lysophosphatidic acid (oleoyl-sn-glycero-3-phos-
phate, LPA). All of these surfaces and soluble activators, with 
the exception of albumin and ristocetin, are of obvious physi-
ological importance. The inclusion of bacteria-derived ristoce-
tin is motivated since it stimulates the otherwise flow-depen-
dent interaction between von Willebrand factor (vWf) and gly-
coprotein (GP)-Ib-IX-V on platelets [19]. Albumin was included 
both as a negative control for basal adhesion and because it 
allows the detection of LPA-induced adhesion [20]. This exper-
imental setup also allows investigation of both α2β1-dependent 
adhesion to collagen and αIIbβ3-dependent adhesion to fibrino-
gen and albumin [21]. Since platelet adhesion is scarcely stud-
ied in ET, our aim was to investigate if this novel assay for 
measurement of static platelet adhesion could be used to 
detect platelet abnormalities in patients with ET. 
Material and Methods 
Patients and Control Subjects
The study included 30 ET patients (Table 1), diagnosed 
according to the World Health Organization (WHO) classifica-
tion  of tumors for 2008. Inclusion was made consecutively 
during a one-year period. Fourteen healthy controls (4 female, 
10 male) with a median age of 49 years (range: 31-66 years) 
were also included. All controls were free from non-steroidal 
anti-inflammatory drugs or other drugs known to affect platelet 
function and were included consecutively during the same time 
period as the patients. The study conforms to the principles 
outlined in the Declaration of Helsinki (1975) and later revisions, 
and was approved by the ethical committee at the Faculty of 
Health Sciences in Linköping, Sweden (Dnr 03-043). All sub-
jects gave their informed consent to be included in the study.
 
Coating of Microplates
The wells of 96-well microplates (Nunc Maxisorp, Roskilde, 
Denmark) were coated with different proteins by addition of 
100 μL of coating solution followed by incubation at 4°C at 
least overnight but for a maximum of 7 days. The different 
protein coating solutions consisted of 2 mg/ml human albumin 
(Pharmacia & Upjohn AB, Stockholm, Sweden), 2 mg/ml 
human fibrinogen (American Diagnostica Inc., Greenwich, 
Connecticut, USA), 10 μg/ml human fibronectin (Roche 
Diagnostics, Mannheim, Germany) or 0.1 mg/ml collagen S 
from calf skin (Roche Diagnostics) combined with 2 μg/ml 
horse tendon collagen (Biopool International, Ventura, 
California, USA). 
 Preparation of Platelet-Rich Plasma (PRP)
Blood was drawn from antecubital veins into Na-heparin 
tubes and centrifuged at 205×g for 20 min at room tempera-
ture (RT). The upper layer consisting of PRP was transferred to 
a new tube and diluted 1:4 in a solution of 0.9% NaCl contain-
ing MgCl2. The final concentration of MgCl2 when performing 
the platelet adhesion assay was 5 mmol/L.
 
Platelet Adhesion Assay
Platelet adhesion was measured as previously described 
[18,21]. Briefly, protein-coated microplates were washed twice 
in 0.9% NaCl by plate inversion followed by addition of 50 μL 
diluted PRP and 50 μL platelet activator or solvent. The platelet 
activators used were ADP and LPA (Sigma-Aldrich, St Louis, 
Missouri, USA), adrenaline (NM Pharma, Stockholm, Sweden) 
and ristocetin (Diagnostica Stago, Asnières-sur-Seine, France). 
The microplates were incubated for 1 h at RT to allow platelet 
attachment and, thereafter, washed twice in 0.9% NaCl by 
plate inversion. To all wells, 140 μL of a substrate buffer solu-
tion (pH 5.4) consisting of 0.1 mol/L sodium citrate, 0.1 mol/L 
citric acid, 0.1% (w/v) Triton X-100 and 1 mg/ml p-nitrophenyl 
phosphate (Sigma-Aldrich) was added. A separate microplate 
was used for estimation of 100% and 0% platelet adhesion. 
This was achieved by mixing 140 μL substrate solution with 50 
μL diluted PRP or 50 μL 0.9% NaCl, respectively. Background 
absorbance was then measured for all wells at 405 nm using 
a Spectramax microplate reader (Molecular Devices, Sunnyvale, 
California, USA) and the microplates were incubated for 40 min 
during constant shaking at RT. After incubation, 100 μL of 2 
mol/L NaOH was added to all wells followed by absorbance 
measurements at 405 nm. Percentage platelet adhesion was 
calculated from the absorbance values. 
It has previously been shown that for absorbance values 
between 0 and 1, the platelet count correlates well with the 
amount of product developed [18]. When performing the same 
type of analysis on one single patient with high platelet count 
we found that linear relationships between absorbance and 
platelet amount can be expected for absorbance values as 
high as 1.9 (r2 = 0.98). 
Allele-Specific Polymerase Chain Reaction (PCR)
Blood samples from ET patients were analyzed for the 
JAK2 mutation (Val617Phe) as described earlier [9]. The only 
difference compared to the original protocol was the use of 35 
PCR-cycles instead of 36. 
Statistics
The effect of externally added platelet activators was ana-
lyzed with one-way Repeated Measures ANOVA followed by 
Bonferroni’s multiple comparison test. Two-way ANOVA and 
Bonferroni’s post test were used for comparisons between 
controls and patients. For the two-way ANOVA, all effects 
induced by externally added activators were analyzed as the 
effect measured reduced by the basal adhesion. The age dis-
tributions for controls and ET patients were analyzed with t-test 
and one-way ANOVA. The effect of JAK2 status on platelet 
adhesion was analyzed with t-test. Linear regression was used 
when investigating the influence of platelet amount on platelet 
adhesion and when analyzing the relationship between platelet 
amount and measured absorbance. All statistical calculations 
were performed using the software GraphPad Prism®, version 
4 (GraphPad Software Inc., San Diego, California, USA).
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The aim of this study was to investigate whether platelets 
from ET patients show abnormal adhesion patterns compared 
to controls. Several patients were older than 70 years, which 
resulted in difficulties in finding age-matched healthy controls. 
Consequently, the control group was significantly younger than 
the patient group (p<0.01), and since age is considered a risk 
factor for thrombosis in ET [8], there is a potential risk that age 
might influence the results. To be able to compare the control 
group with the ET patients, we therefore divided the ET group 
in two, with one group being age-matched with the controls 
and the other group consisting of patients ≥ 67 years. The 
ages of the controls (n = 14, median age: 49, range: 31-66) 
and the age-matched ET patients (n = 14, median age: 49, 
range: 30-66) were similar. However, the ages of the patients 
≥ 67 years (n = 16, median age: 77, range: 67-87) were sig-
nificantly different from the other two groups (p<0.001) 
The prevalence of ASA-treatment was similar for the age-matched 
ET patients (8 of 14) and the patients ≥ 67 years (9 of 16).
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Figure 1. Platelet adhesion to albumin (a), collagen (b), fibrinogen (c), and fibronectin (d) was significantly increased by ADP (1 and 10 μmol/L) for both 
controls and ET-platelets. A dose-response relationship was seen on all surfaces for ET-platelets, but only on albumin and fibronectin for controls. Differ-
ences in basal adhesion (solvent) between the three groups were not significant. Data are presented as mean+SD. Filled bars = Controls (n = 11 except 
for fibronectin where n = 10, age range: 31-63 years), open bars = Age-matched patients (n = 14, age range: 30-66 years), patterned bars = Patients ≥ 
67 years (n = 16, age range: 67-87 years). ns = not significant, **p<0.01, ***p<0.001
Figure 2. The combination of 0.1 μmol/L adrenaline (Adr) and 10 μmol/L 
LPA increased platelet adhesion synergistically to albumin for both ET-
platelets and controls. Data are presented as mean+SD. Filled bars = Con-
trols (n = 11, age range: 31-63 years), open bars = Age-matched patients 
(n = 14, age range: 30-66 years), patterned bars = Patients ≥ 67 years 
(n = 16, age range: 67-87 years). ns = not significant, **p<0.01, ***p<0.001
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Platelet Adhesion
Our approach was to measure platelet adhesion to protein 
surfaces in the presence or absence of different externally 
added platelet activators. Basal adhesion to the different pro-
teins in the absence of external activators (solvent) was not 
significantly different between the three groups (Figure 1). 
Addition of 1 and 10 μmol/L ADP significantly increased plate-
let adhesion to all surfaces for controls as well as for both 
patient groups (Figures 1a-d). Furthermore, there was a sig-
nificant dose-response relationship on all surfaces when acti-
vating ET-platelets with ADP. For control platelets, this was 
only seen on albumin and fibronectin, i.e. the surfaces that 
induced the lowest adhesion. The only significant effects 
observed for adrenaline at 0.1 μmol/L and ristocetin at 1 mg/
ml were increased adhesion to collagen and fibrinogen for both 
ET-platelets and controls as well as increased ristocetin-
induced adhesion to albumin for ET-platelets (not shown). 
When combining 0.1 μmol/L adrenaline and 10 μmol/L LPA, 
Figure 3b
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Figure 3. Platelet adhesion to albumin (filled circles), collagen (triangles) and fibrinogen (squares) induced by ADP (1 and 10 μmol/L), ristocetin (Risto 1 
mg/ml) or the combination of adrenaline (Adr 0.1 μmol/L) and LPA (10 μmol/L) with basal adhesion subtracted. The increase in platelet adhesion induced 
by the soluble platelet activators was generally higher for ET patients compared to controls (n = 12-14, age range: 31-66 years except in D where age 
range: 31-63 years) and there were no differences between age-matched patients (n = 14, age range: 30-66 years) and patients ≥ 67 years (n = 16, age 
range: 67-87 years). Horizontal lines represent mean values. ns = not significant, *p<0.05, **p<0.01, ***p<0.001
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nsadhesion of control- and ET-platelets to albumin was signifi-
cantly increased compared to basal adhesion (solvent) and 
compared to adrenaline and LPA when added alone (Figure 2). 
This pattern of increased adhesion indicating synergistic 
effects was neither detected for controls nor ET-platelets on 
collagen and fibrinogen, but was present on fibronectin for 
both ET-groups but not for controls (not shown). 
Comparisons of Platelet Adhesion Between Controls 
and ET Patients
When analyzing differences between the groups, we focused 
on those activators that produced significantly increased platelet 
adhesion for controls and both patient groups. Comparisons were 
made on the increase relative to basal adhesion induced by the 
externally added activators. For 10 μmol/L ADP on fibrinogen, the 
increase was significantly higher for age-matched patients com-
pared to controls, while there was no difference between controls 
and patients ≥ 67 years (Figure 3a). Inversely, adding 10 μmol/L 
ADP or the combination of adrenaline and LPA to albumin as well 
as 1 μmol/L ADP to collagen or 1 mg/ml ristocetin to fibrinogen 
resulted in significantly greater increase in adhesion for patients ≥ 
67 years but not for age-matched ET patients compared to con-
trols (Figures 3a-d). The increased adhesion to collagen induced 
by 10 μmol/L ADP and 1 mg/ml ristocetin was significantly higher 
for both age-matched patients and patients ≥ 67 years compared 
to controls (Figures 3b, c). None of the activating stimuli induced 
significant differences between the patient groups (Figures 3a-d). 
 
Influence of Platelet Amount, History of 
Thrombohemorrhagic Events and JAK2 Status on 
Platelet Adhesion
Since ET patients have more platelets than healthy individu-
als, we investigated if the increased platelet activity found in 
this study could be explained by this quantitative difference. In 
the cases where we observed a significant difference in the 
increase in platelet adhesion (1 μmol/L ADP to collagen; 10 
μmol/L ADP to albumin, collagen and fibrinogen; 1 mg/ml ris-
tocetin to collagen and fibrinogen; 0.1 μmol/L adrenaline + 10 
μmol/L LPA to albumin), we performed linear regression analy-
ses for the amount of ET-platelets added to wells versus plate-
let adhesion. Platelet amount was estimated by measurements 
of acid phosphatase activity, which correlates well with the 
actual platelet count [18]. However, there were no significant 
correlations between platelet amount and adhesion since 
r2-values ranged from 0.0099 to 0.094 for the seven different 
stimuli. 
Even though we found significant differences in platelet 
adhesion for ET patients compared to controls, we also found 
considerable variations within groups and consequently over-
laps between the groups. We therefore further analyzed the 
results with specific attention to adhesion values for ET-platelets 
being higher than the mean + 2 standard deviations (SDs) cal-
culated for controls (Figure 4) as described earlier [22]. 
Adhesion above mean + 2 SD was found for approximately 
50% of the patients when investigating ristocetin and ADP-
induced adhesion to collagen and fibrinogen. The prevalence 
of such high adhesion values was considerably lower on the 
albumin surface. Furthermore, this pattern remained in both 
the age-matched patient group and in patients ≥ 67 years (not 
shown). In order to investigate whether a high adhesion phe-
notype could be connected to a history of thrombosis, we 
studied the disease characteristics of patients having adhesion 
above mean + 2 SD for five or more of the seven stimuli. 
However, this small group of nine patients was heterogeneous, 
containing patients suffering from bleeding and thrombosis as 
well as no events at all. At the time of blood sampling, five of 
those patients received a combination of anti-proliferative and 
anti-platelet treatment (hydroxyurea + ASA), one received 
hydroxyurea combined with warfarin, and three patients were 
untreated. Among the remaining 21 patients, three were 
treated with both anti-proliferative and anti-platelet drugs (ASA 
combined with hydroxyurea or with a history of P32-treatment). 
Also, for one of the three untreated patients in the high adhe-
sion phenotype group, management of the disease was later 
changed to treatment with both hydroxyurea and ASA. A 
change from monotherapy into combined anti-platelet and 
anti-proliferative treatment (ASA+hydroxyurea or interferon) 
occurred in three patients in the larger group of 21 patients. 
We next investigated the influence on platelet adhesion of the 
recently discovered mutation in the JAK2 gene (Val617Phe), 
which is present in about 60% of all ET patients [12]. JAK2 
status was available for eight of the nine patients described 
above who had highly adhesive platelets (one patient died dur-
ing the course of the study). Four of those patients were JAK2-
positive and four were JAK2-negative. Among all patients 
analyzed for JAK2 status in this study (25 patients), 15 were 
negative and 10 were positive. When investigating the whole 
patient group, there were no differences between JAK2-
positive and JAK2-negative patients regarding platelet adhe-
sion induced by the stimuli that caused differences between 
controls and patients. 
Figure 4. The relative proportion of all ET patients presenting with platelet 
adhesion to albumin (Alb), collagen (Coll) and fibrinogen (Fibrg) exceeding 
the mean + 2SD of the control group for different activating stimuli with 
basal adhesion subtracted (n = 30, age range: 30-87 years). Numerals on 
the x-axis represent concentrations of soluble platelet activators in μmol/L 
except for ristocetin where the unit of concentration is mg/ml. Adr = adren-
aline, Risto = ristocetin
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Different types of ex vivo platelet function measures have 
reported that ET-platelets are highly active. Flow cytometric 
studies in whole blood show increased platelet surface expres-
sion of P-selectin, increased binding of thrombospondin to 
platelets and increased amounts of platelet-leukocyte aggre-
gates in MPN patients compared to controls [22,23]. Urine 
from ET patients has been reported to contain increased 
amounts of TXA2-metabolites [24]. Compared to normal sub-
jects, an increased amount of platelet aggregates has been 
observed in blood from ET patients, and there is also an 
increased spontaneous aggregation of ET-platelets in plasma 
[25]. All those studies could potentially be used to explain the 
preponderance of thrombosis compared to bleeding in ET. 
However, interpretations get complicated when taking into 
account results obtained from analyses that activate platelets 
in vitro. In a study including 120 MPN patients, platelet aggre-
gation was measured both in whole blood and in PRP after in 
vitro stimulation [26]. Platelets were hyperreactive when mea-
suring whole blood aggregometry and using ADP and collagen 
as activators. In contrast, aggregation in PRP was decreased. 
Decreased platelet aggregation response in PRP to different 
platelet agonists for MPN patients has been reported by a 
number of other studies [27-30]. Decreased platelet function 
has also been observed with whole blood flow cytometry after 
in vitro activation [22] and when using the Platelet Function 
Analyzer (PFA-100) [30]. In accordance with this, we found a 
non-significant trend towards decreased basal adhesion to 
collagen and fibrinogen for ET-platelets in the present study. In 
contrast to these results, ET-platelets produce increased 
amounts of thromboxane B2 as compared to controls after in 
vitro stimulation with thrombin [31]. Regarding platelet aggre-
gation in PRP, the most pronounced decrease in platelet func-
tion is often seen with adrenaline as activator [27,29,30]. This 
has been proposed to be the result of decreased amounts of 
α-adrenergic receptors [32]. However, this is opposite to our 
results, which show that ET-platelets have normal response to 
adrenaline alone and increased reactivity compared to controls 
when combined with LPA. Further, we observed a consider-
able individual variability both in controls and in ET patients 
regarding the combination of adrenaline and LPA. The appear-
ance of individual variability in the response to adrenaline has 
been studied in the healthy population, and when including 
140 individuals, 16% were classified as non-responders to 
adrenaline-induced platelet aggregation in plasma [33]. This 
variability in the adrenaline response in healthy subjects has 
been confirmed by other investigations also studying platelet 
function in plasma [20,34-36]. No study has been designed 
with the purpose of investigating individual variability of adren-
aline-response in ET patients. However, when looking at indi-
vidual variations obtained from studies investigating platelet 
aggregation in PRP for patients with MPNs, we find it possible 
that the variability exists in this group as well [30,32,37]. 
Particularly interesting is a study that investigated 76 MPN 
patients, and characterized 21% of patients as non-respond-
ers to adrenaline measured by aggregometry in PRP [27]. 
These results are very similar to the study on healthy donors 
described above, which reported 16% of healthy individuals as 
non-responders to adrenaline [33]. Our study, showing inter-
individual variation in the response to adrenaline combined 
with LPA, further supports the claim that the response to 
adrenaline in the ET population is highly heterogeneous. 
Furthermore, the increased response to adrenaline observed 
by us and not by others might be a result of the methodology 
used (described below). 
Age is a well-known risk factor for thrombosis in ET [8,38]. 
In agreement with this, our results show higher adhesion val-
ues for patients ≥ 67 years versus controls, which correlate 
well with the increased thrombosis risk in this group. We also 
found that some stimuli were significantly more effective in 
inducing platelet adhesion on age-matched patients compared 
to controls, while differences between the two patient groups 
were lacking. A plausible explanation is that part of the increase 
in adhesion is connected to old age while the other part is con-
nected to the disease itself. 
Our general finding in this study was that ET-platelets are 
more readily activated compared to controls. However, there 
was an overlap between the groups with several patients hav-
ing responses in the same range as the control group. Since 
the JAK2 mutation occurs in only approximately 60% of ET 
patients [12], we decided to investigate if patients with high 
adhesion values were JAK2-positive. However, JAK2 status 
did not influence platelet adhesion. Furthermore, there were no 
clear connections between platelet adhesion and disease his-
tory. On the other hand, this study included eight patients 
treated with ASA combined with anti-proliferative treatment, 
and five of those were classified as high adhesion phenotype. 
Later, one untreated patient that we classified as high adhesion 
phenotype was, independent of our results, prescribed ASA 
combined with hydroxyurea. From a clinical point of view, it 
might be suggested that these patients, being treated with 
both anti-proliferative and anti-platelet drugs, were considered 
to have a more severe disease and therefore needed more 
extensive treatment. The other patients not classified as high 
adhesion phenotype were less likely to have combined anti-
proliferative and anti-platelet treatment. In this way, a high 
adhesion phenotype seems to be connected to clinical status. 
However, further studies are needed before any definite con-
clusions can be drawn regarding the predictive value of the 
adhesion assay for thrombosis. We aim to follow these patients 
in the future, not only for the purpose of detecting thrombosis-
prone individuals but also for investigating the abilities of the 
assay to guide anti-thrombotic treatment. 
It might be claimed that our use of PRP without the com-
monly performed adjustment of platelet count with autologous 
platelet-poor plasma (PPP) limits this study. However, recent 
studies have shown that adjustment of platelet count with PPP 
might induce decreased platelet activity, possibly through an 
inhibiting effect from PPP [39,40]. This suggests that compari-
sons between control platelets and platelets from ET patients 
might be misleading if adjusting the platelet count since the 
higher platelet count for ET patients demands more PPP for 
dilution [40]. Consequently, the increased adhesion for 
ET-platelets observed in this study might be the result of avoid-
ance of PPP-induced artificial inhibition.
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in vivo results in circulating exhausted platelets that are not 
able to respond in vitro [41]. This explanation might also be of 
interest for the interpretation of the current results. We suggest 
that the increased reactivity in vitro observed by us, which is 
uncommon for other in vitro tests, might be a consequence of 
the relatively long one hour incubation period in the presence 
of both an activating surface and soluble agonists. This is 
rather different from e.g. flow cytometry and platelet 
aggregometry, which often measure platelet response within 
minutes after stimulation with a single agonist. We also noticed 
that strong stimuli such as high concentrations of ADP and 
ristocetin combined with the activating surfaces collagen and 
fibrinogen resulted in a relatively high proportion of adhesion 
values being higher than the mean + 2SD for controls. In con-
trast, weaker stimuli represented by adhesion measured on 
albumin resulted in comparatively few adhesion values that 
were higher than the control mean + 2SD. In addition, earlier 
studies show that secretion of ADP is important in this assay 
[20,21]. Thus, we propose that multiple stimuli, which most 
likely are of importance in vivo [42], and a long incubation time 
are both needed to induce secretion and activation of exhaust-
ed ET-platelets. 
In conclusion, we suggest that the present platelet assay 
mimics the in vivo situation regarding the presence of chronic 
platelet-activating stimuli resulting in increased risk of thrombo-
sis. It must be remembered, however, that additional factors, 
such as vascular cells other than platelets and shear stress, are 
absent in our assay but affect thrombus formation in vivo. 
Nevertheless, the assay is reproducible over time [43] and it 
might be useful to predict thrombotic risk and monitor anti-
platelet treatment in ET. Further prospective follow-up studies 
and larger patient material are needed to strengthen this 
hypothesis.
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